Leerink Partners Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $72

Leerink Partners analyst Mani Foroohar maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Perform and raises the price target from $61 to $72.